Login / Signup

Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study.

Christophe SchmittLaura BrockwellMylène GiraudonMauro ZucchettoLisa ChristBettina BannertThomas DaikelerPeter M Villiger
Published in: Arthritis research & therapy (2022)
ClinicalTrials.gov , NCT03923738.
Keyphrases
  • giant cell
  • rheumatoid arthritis
  • high dose
  • juvenile idiopathic arthritis
  • systemic lupus erythematosus
  • replacement therapy